GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beximco Pharmaceuticals Ltd (DHA:BXPHARMA) » Definitions » Equity-to-Asset
中文

Beximco Pharmaceuticals (DHA:BXPHARMA) Equity-to-Asset : 0.64 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Beximco Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Beximco Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was BDT45,106 Mil. Beximco Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was BDT70,627 Mil. Therefore, Beximco Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.64.

The historical rank and industry rank for Beximco Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

DHA:BXPHARMA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.59   Med: 0.66   Max: 0.75
Current: 0.64

During the past 13 years, the highest Equity to Asset Ratio of Beximco Pharmaceuticals was 0.75. The lowest was 0.59. And the median was 0.66.

DHA:BXPHARMA's Equity-to-Asset is ranked better than
58.88% of 1087 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs DHA:BXPHARMA: 0.64

Beximco Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for Beximco Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beximco Pharmaceuticals Equity-to-Asset Chart

Beximco Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.60 0.65 0.71 0.61 0.63

Beximco Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 0.60 0.62 0.63 0.64

Competitive Comparison of Beximco Pharmaceuticals's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beximco Pharmaceuticals's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Beximco Pharmaceuticals's Equity-to-Asset falls into.



Beximco Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Beximco Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Equity to Asset (A: Jun. 2023 )=Total Stockholders Equity/Total Assets
=43680.704/69156.783
=0.63

Beximco Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=45106.257/70626.673
=0.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beximco Pharmaceuticals  (DHA:BXPHARMA) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Beximco Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Beximco Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Beximco Pharmaceuticals (DHA:BXPHARMA) Business Description

Traded in Other Exchanges
Address
19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals Ltd is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from local sales.

Beximco Pharmaceuticals (DHA:BXPHARMA) Headlines

No Headlines